BRIEF—Shorla and Eversana launch Jylamvo

Irish-American specialty pharma company Shorla Oncology and Eversana, a provider of commercialization services to the life sciences industry, have announced the US commercial launch of Jylamvo (methotrexate) oral solution, the first and only oral methotrexate solution approved in the USA for use in adults.

Jylamvo is approved to treat adults with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen, mycosis fungoides as a single agent or as part of a combination chemotherapy regimen, relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen, rheumatoid arthritis and severe psoriasis.

Sharon Cunningham, chief executive of Shorla, said: “We are delighted to introduce Jylamvo as an alternative treatment option for patients who may have difficulty swallowing pills.

“This is our second product launch in the US market in 2023, and today’s announcement is another significant advancement in our pipeline and our mission to bring new therapeutic options to patients in need.”

Jim Lang, chief executive, Eversana, added: “We have immediately activated our full commercialization engine, combined with in-depth knowledge of the complex methotrexate market, to help patients who have waited far too long for other treatment options that can help meet their needs.

“Today’s announcement showcases the partnership we have built with the Shorla team, and we look forward to continuing to support their growing portfolio of therapies for patients in need.”